昭衍新藥(603127.SH):昭衍檢測近期獲得營業執照
格隆匯 8 月 4日丨昭衍新藥(603127.SH)公佈,公司基於戰略需求和業務拓展,投資人民幣2000萬元設立全資子公司昭衍(北京)檢測技術有限公司(“昭衍檢測”),主要從事臨牀醫學檢測服務。此次投資未達到董事會和股東大會的審批標準,亦不屬於關聯交易和重大資產重組事項。
昭衍檢測於近期獲得北京市工商行政管理機關頒發的《營業執照》,其經營範圍:技術開發;技術諮詢;技術交流;技術服務;技術檢測;醫學研究與試驗發展
隨着國家及製藥企業對創新藥研發的重視和持續增加的投資,國內臨牀檢測行業未來將繼續保持快速發展。公司基於未來的臨牀檢測市場需求和客户服務需要,決定成立全資子公司昭衍(北京)檢測技術有限公司,精耕臨牀檢測領域。昭衍檢測傳承母公司昭衍新藥成熟的生物樣本分析平台體系、豐富的方法開發及檢測經驗以及完善的質量體系,搭建起了高質量的小分子藥物檢測平台、大分子藥物檢測平台、基因及細胞治療藥物的樣本檢測平台及生物標誌物的檢測平台,可以為客户提供專業、高質量的第三方中心實驗室服務,有利於提升公司醫藥研發外包服務的綜合能力和整體競爭力,培養公司新的利潤增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.